Fairvalue-Calculator Fairvalue-Calculator
EN DE

PharmaCielo Ltd (PCLO) Fair Value & Analysis

Healthcare · CA · Market cap C$19.7M

PriceC$0.0700
Fair ValueC$0.0600
Upside-14.3%
Quality92/100
Evidence: Low Range C$0.0500 – C$0.0800

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PharmaCielo Ltd (PCLO) currently trades at C$0.0700, while our model-based Fair Value estimate is C$0.0600 — implying the stock looks roughly 14.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies. PharmaCielo Ltd. is headquartered in Toronto, Canada.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is PharmaCielo Ltd (PCLO) undervalued?
As of Jun 23, 2026, our model estimates a fair value of C$0.0600 versus a price of C$0.0700 — about −14% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PCLO?
Our 21-model fair value for PharmaCielo Ltd is C$0.0600 (as of Jun 23, 2026), built from audited fundamentals. The current price is C$0.0700.
What is the quality score of PCLO?
PharmaCielo Ltd has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.